KNSA KINIKSA PHARMACEUTICALS INTERNATIONAL PLC Earnings Reports 8-K Filing 2025 - Financial Results Kiniksa Pharmaceuticals reported ARCALYST net product revenue of $121.9 million for Q4 2024 and $416.4 million for the full year, with $243.6 million in cash and investments as of December 31, 2024.Get access to all SEC 8-K filings of the KINIKSA PHARMACEUTICALS INTERNATIONAL PLC